AbbVie Receives FDA CRL for Wrinkle Drug Due to Manufacturing Concerns
AbbVie Inc. (ABBV) shares fell in premarket trading after the FDA issued a Complete Response Letter (CRL) for its wrinkle drug TrenibotE, citing manufacturing process concerns. The FDA did not raise safety or efficacy issues, and AbbVie remains confident in addressing the feedback. The company plans to resubmit its application soon.
Tickers: $ABBV
Topics: AbbVie drug approval FDA manufacturing issues TrenibotE